Clinical trial

Spirulina Supplementation in Postmenopausal Women

Opening soon · Not applicable · 1 countries · Registry ID NCT07718399

Opening soonNot applicableInterventional

What this study is about

The purpose of this study is to investigate the effects of spirulina supplementation on weight gain associated with menopause, changes in metabolic parameters, sleep quality, and markers of depression in mildly overweight postmenopausal women, and to evaluate the changes that occur in these parameters.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age45 Years to 65 Years

SexFemale

Healthy volunteersAccepted

ConditionPostmenopause, Overweight

Full registry criteria

Inclusion Criteria: * Volunteering to participate in the study * Having a body mass index (BMI) between 25 and 29.9 kg/m² * Having no chronic illnesses * Being between the ages of 45 and 65 * Being postmenopausal * Willing to consume the provided supplement * Individuals who can read and write in Turkish and are open to communication. Exclusion Criteria: * Having a chronic condition such as diabetes, hypertension, cancer, metabolic syndrome, chronic kidney disease, dyslipidemia, etc. * Having a congenital metabolic disorder * Being in the experimental group but not taking the supplement regularly * Taking medication to lower blood lipids * Having an allergy to any food * Not being in the postmenopausal period

Treatments and study arms

Spirulina

Dietary Supplement

Participants will receive 2 g/day spirulina tablets for 8 weeks.

Placebo

Other

Participants will receive matching placebo tablets for 8 weeks.

Primary outcomes

Fasting Blood GlucoseBaseline and Week 8

Fasting blood glucose (mg/dL) will be measured at baseline and Week 8 to evaluate the effect of spirulina supplementation.

HbA1cBaseline and Week 8

HbA1c (%) will be measured at baseline and Week 8 to assess long-term glycemic control.

HOMA-IRBaseline and Week 8

Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) will be calculated using fasting glucose and fasting insulin measurements obtained at baseline and Week 8.

Total CholesterolBaseline and Week 8

Total cholesterol concentration (mg/dL) will be measured at baseline and Week 8.

LDL CholesterolBaseline and Week 8

Low-density lipoprotein (LDL) cholesterol concentration (mg/dL) will be measured at baseline and Week 8.

HDL CholesterolBaseline and Week 8

High-density lipoprotein (HDL) cholesterol concentration (mg/dL) will be measured at baseline and Week 8.

TriglyceridesBaseline and Week 8

Serum triglyceride concentration (mg/dL) will be measured at baseline and Week 8.

Study locations

1 locations were listed when this page was built. The first 40 are shown.

Haliç University Faculty of Health Sciences🌐 Istanbul, eyüpsultan, Turkey (Türkiye)

Open map

Niran Çomak, DietitianContact

Email · Call 905432670224